Amarin (AMRN) Vascepa NCE Not in Latest FDA Orange Book Update
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin's (Nasdaq: AMRN) Vascepa NCE is not in the latest U.S. FDA Orange Book update. To visit the FDA page, click here.
Shares are down 0.4 percent Friday.
Shares are down 0.4 percent Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin highlights Vascepa cost advantage over new injectable rivals
- Abbisko and AstraZeneca to trial oral PD-L1 drug with Tagrisso
- Brii Bio reports mixed Phase 2b hepatitis B trial results
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
